On Tuesday, Ocular Therapeutix Inc (NASDAQ: OCUL) opened higher 2.71% from the last session, before settling in for the closing price of $8.11. Price fluctuations for OCUL have ranged from $4.79 to $11.77 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 72.05%. Company’s average yearly earnings per share was noted -17.19% at the time writing. With a float of $133.71 million, this company’s outstanding shares have now reached $159.26 million.
Let’s determine the extent of company efficiency that accounts for 274 employees. In terms of profitability, gross margin is 90.66%, operating margin of -342.52%, and the pretax margin is -323.44%.
Ocular Therapeutix Inc (OCUL) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ocular Therapeutix Inc is 16.06%, while institutional ownership is 74.31%. The most recent insider transaction that took place on Jun 02 ’25, was worth 111,581. In this transaction Chief Medical Officer of this company sold 13,861 shares at a rate of $8.05, taking the stock ownership to the 206,805 shares. Before that another transaction happened on Jun 02 ’25, when Company’s Officer proposed sale 13,861 for $8.05, making the entire transaction worth $111,524.
Ocular Therapeutix Inc (OCUL) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -17.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.61% during the next five years compared to 8.51% growth over the previous five years of trading.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
Check out the current performance indicators for Ocular Therapeutix Inc (OCUL). In the past quarter, the stock posted a quick ratio of 10.14. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 22.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.15, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.39 in one year’s time.
Technical Analysis of Ocular Therapeutix Inc (OCUL)
Looking closely at Ocular Therapeutix Inc (NASDAQ: OCUL), its last 5-days average volume was 2.44 million, which is a jump from its year-to-date volume of 1.48 million. As of the previous 9 days, the stock’s Stochastic %D was 85.11%. Additionally, its Average True Range was 0.53.
During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 75.86%, which indicates a significant decrease from 84.75% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.05% in the past 14 days, which was lower than the 79.22% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.45, while its 200-day Moving Average is $8.46. However, in the short run, Ocular Therapeutix Inc’s stock first resistance to watch stands at $8.66. Second resistance stands at $9.00. The third major resistance level sits at $9.37. If the price goes on to break the first support level at $7.96, it is likely to go to the next support level at $7.59. Now, if the price goes above the second support level, the third support stands at $7.25.
Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats
There are currently 159,300K shares outstanding in the company with a market cap of 1.33 billion. Presently, the company’s annual sales total 63,720 K according to its annual income of -193,510 K. Last quarter, the company’s sales amounted to 10,700 K and its income totaled -64,050 K.
